1. In April, the FDA approved Nuplazid as the first drug approved to treat hallucinations and delusions in people with Parkinson’s disease.
2. The agency approved Ocaliva in May to treat a rare chronic liver disease known as primary biliary cirrhosis.
3. Epclusa is the first drug approved by the FDA for all six forms of hepatitis C. The treatment was approved in June.
4. The FDA approved Exondys 51 in September. It is the first treatment for Duchenne’s muscular dystrophy, a rare degenerative condition that causes muscle weakness, loss of movement and eventually death.
5. Spinraza is the first available treatment for patients with spinal muscular atrophy. The drug was approved in December.
6. The FDA approved Rubraca in December as a new treatment for women with advanced ovarian cancer.
More articles on supply chain:
Trump slams drugmakers at press conference: ‘They’re getting away with murder’
St. Jude Medical releases cybersecurity updates for vulnerable heart devices
Egalet earns FDA approval for abuse-deterrent opioid painkiller
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
